Zynex INC 8-K filings

Zynex, Inc. successfully exited Chapter 11 bankruptcy, implementing a reorganization plan that included new financing, cancellation of all prior equity, and significant corporate governance changes.

Zynex, Inc. has received court confirmation for its Chapter 11 reorganization plan, which will cancel existing common stock and transfer ownership to a new Plan Sponsor.

Zynex, Inc. announced the conclusion of an SEC investigation with no enforcement action intended, amidst ongoing Chapter 11 bankruptcy proceedings and delisting from Nasdaq.

Zynex, Inc. announced its common stock delisting from Nasdaq and subsequent trading on the Pink Limited Market, alongside filing an amended Chapter 11 reorganization plan.

Zynex, Inc. removed its Chair, Thomas Sandgaard, following his federal indictment for healthcare and securities fraud, as the company navigates Chapter 11 bankruptcy and Nasdaq delisting.

Zynex, Inc. has amended its debtor-in-possession financing and filed a joint plan of reorganization as it navigates Chapter 11 bankruptcy proceedings.

Zynex, Inc. and its subsidiaries have filed for Chapter 11 bankruptcy, secured $22.3 million in debtor-in-possession financing, and face delisting from Nasdaq.

Zynex, Inc. announced it has voluntarily entered Chapter 11 bankruptcy for financial restructuring with new financing from its lenders, aiming for long-term success.

Zynex, Inc. reported a significant decline in third-quarter 2025 revenue and a substantial net loss, leading to a missed interest payment on its convertible notes and a strategic review of its financial future.

Zynex, Inc. announced the finalization of separation terms with former Chief Commercial Officer Anna Lucsok, including severance and accelerated vesting of restricted shares.

Zynex, Inc. announced the appointment of Bret W. Wise to its Board of Directors and as Chair of the Audit Committee, alongside a Chief Commercial Officer resignation.

Zynex, Inc. announced a strategic shift for its NiCO CO-Oximeter, seeking a commercialization partner and incurring up to $31 million in impairment charges.

Zynex, Inc. announced Anna Lucsok's transition from Chief Operating Officer to Chief Commercial Officer, reallocating some of her previous responsibilities.

Zynex, Inc. announces the appointment of new Chief Financial Officer, Chief Legal Officer, and other key leadership roles, strengthening its executive team.

Zynex, Inc. announced a significant net loss of $20.0 million in Q2 2025, down from a $1.2 million profit in the prior year, driven by a sharp revenue decline and operational restructuring, while also appointing a new CEO and submitting a new product to the FDA.

Zynex, Inc. announced that Chief Financial Officer Dan Moorhead will resign effective August 29, 2025, with plans for a consulting agreement to ensure a smooth transition.

Zynex, Inc. announced that Tricare, its largest insurance customer, has decided to continue the temporary payment suspension, pending further review.

Zynex, Inc. announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025, succeeding founder Thomas Sandgaard who will remain Chairman of the Board.

Zynex, Inc. has announced a reduction of 86 corporate roles, representing 14% of its workforce, anticipating $5 million in annualized cost savings, while also appealing a temporary payment suspension by Tricare.

Zynex, Inc. held its Annual Meeting of Stockholders on May 15, 2025, and elected directors and ratified the appointment of its independent accounting firm.

Zynex, Inc. has submitted a 510(k) application to the FDA for its NiCO, Noninvasive CO-Oximeter device, a laser-based pulse oximeter designed to improve accuracy and address limitations of current devices.

Zynex reports a significant drop in revenue and a net loss for Q1 2025, impacted by a temporary payment suspension from Tricare and reduced sales force.

Zynex, Inc. reports that Marcum LLP resigned as their independent registered accounting firm and CBIZ CPAs P.C. was engaged as the new firm, effective immediately on March 26, 2025.

Zynex, Inc. repurchased 1.7 million shares of its common stock from Chairman, President, and CEO Thomas Sandgaard at a price of $2.905 per share.

Zynex reports a 4% increase in full-year 2024 net revenue to $192.4 million but announces a 15% staff reduction due to payment suspensions from Tricare.

Zynex, Inc. announced a 13% year-over-year increase in orders and $50 million in net revenue for the third quarter of 2024, along with FDA clearance for their new TensWave device.

Zynex, Inc. announced an 11% year-over-year revenue increase for the second quarter of 2024, reaching $49.9 million, while also revising its full-year revenue guidance due to strategic shifts.

Zynex, Inc. held its annual meeting on May 16, 2024, electing four directors and ratifying its independent auditor.

Zynex, Inc. announced a 10% year-over-year revenue increase to $46.5 million for the first quarter of 2024, although results were slightly below guidance due to a cyber incident affecting insurer payments.

Zynex, Inc. reported a 17% increase in revenue for 2023, reaching $184.3 million, and announced a new $20 million stock repurchase program.